NEW GLP3 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?
- Dave Knapp
- 1 hour ago
- 1 min read
On this episode of On the Pen, Dave breaks down Novo Nordisk’s decision to slash list prices for Wegovy and Ozempic starting in 2027, alongside new head-to-head data showing tirzepatide outperforming Novo’s next-gen combo CagriSema in weight loss. Dave also explores promising early results from triple-agonist drugs and the FDA approval of the Allurion Balloon, highlighting how the obesity treatment landscape is rapidly expanding beyond injections toward more personalized and accessible options.
What are your thoughts about this data drop and the Allurion Balloon?
This article is reader-supported on Substack.
To receive new posts and support my work,
consider becoming a free or paid subscriber.
Comments